Literature DB >> 19289615

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

Pernille Lassen1, Jesper G Eriksen, Stephen Hamilton-Dutoit, Trine Tramm, Jan Alsner, Jens Overgaard.   

Abstract

PURPOSE: A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16(INK4A) in these tumors. We evaluated p16(INK4A) as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial. PATIENTS AND METHODS: Immunohistochemical expression of p16(INK4A) was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16(INK4A) status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated.
RESULTS: p16(INK4A) positivity was found in 35 tumors (22%). Tumor-positivity for p16(INK4A) was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16(INK4A) remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68).
CONCLUSION: Expression of p16(INK4A) has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289615     DOI: 10.1200/JCO.2008.20.2853

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  169 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

3.  Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Authors:  Thomas J Galloway; Miriam N Lango; Barbara Burtness; Ranee Mehra; Karen Ruth; John A Ridge
Journal:  Head Neck       Date:  2012-02-02       Impact factor: 3.147

4.  Quantitative diffusion-weighted MRI parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.

Authors:  C S Schouten; P de Graaf; E Bloemena; B I Witte; B J M Braakhuis; R H Brakenhoff; C R Leemans; J A Castelijns; R de Bree
Journal:  AJNR Am J Neuroradiol       Date:  2015-02-26       Impact factor: 3.825

Review 5.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

6.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

7.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

Review 8.  Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Authors:  Ana Markovic; Christine H Chung
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

9.  Diffuse optical measurements of head and neck tumor hemodynamics for early prediction of chemoradiation therapy outcomes.

Authors:  Lixin Dong; Mahesh Kudrimoti; Daniel Irwin; Li Chen; Sameera Kumar; Yu Shang; Chong Huang; Ellis L Johnson; Scott D Stevens; Brent J Shelton; Guoqiang Yu
Journal:  J Biomed Opt       Date:  2016-08-01       Impact factor: 3.170

10.  Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer.

Authors:  Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.